MicuRx Pharmaceuticals, a clinical-stage biopharmaceutical company developing new treatments for drug-resistant bacterial infections, announced that the FDA has cleared its Investigational New Drug (IND) application for MRX-5. The clearance allows the company to initiate a phase 2a clinical trial evaluating the investigational therapy in patients with Mycobacterium abscessus pulmonary disease, a serious and difficult-to-treat non-tuberculous mycobacterial (NTM) infection.
M abscessus pulmonary disease is associated with high morbidity, lengthy and complex treatment regimens, and limited effective therapeutic options. Current standard-of-care approaches often rely on prolonged multi-drug combinations that are poorly tolerated and frequently yield suboptimal outcomes, underscoring the need for new treatment options.
MRX-5 is a novel oral antibacterial agent designed specifically to target NTM infections. In preclinical studies, the compound demonstrated potent activity against clinical isolates of M abscessus, including strains resistant to existing therapies, and showed favorable pharmacokinetic and safety profiles in nonclinical and clinical evaluations.
Learn more:
“The FDA’s clearance of our IND for MRX-5 represents an important milestone for MicuRx and for patients suffering from M abscessus pulmonary disease,” MicuRx President Jerry (Zhiyue) Li, said in a statement. “This approval allows us to advance MRX-5 into a Phase 2a clinical trial, which aims to assess its safety and efficacy in patients.”
What You Need to Know
FDA clearance of the MRX-5 IND enables MicuRx to advance a Phase 2a trial for a serious NTM lung infection with limited treatment options.
MRX-5 has shown promising preclinical activity against drug-resistant M abscessus strains and favorable safety and pharmacokinetic profiles.
The milestone expands MicuRx’s anti-infective pipeline and reinforces its focus on combating antimicrobial resistance.
The phase 2a study will be a multicenter trial conducted in the United States and will enroll adults with confirmed M abscessus pulmonary disease. Data generated from the study are expected to inform future development milestones for MRX-5.
The IND clearance further strengthens MicuRx’s growing clinical pipeline and highlights the company’s ongoing commitment to addressing antimicrobial resistance and other challenging bacterial infections.
About Investigational Compound
MRX-5 is a next-generation antibacterial agent being developed by MicuRx for the treatment of non-tuberculous mycobacterial infections, including M. abscessus. The compound is designed for oral administration and aims to provide a more effective and tolerable treatment option.
FDA granted orphan drug designation to MRX-5 for the treatment of NTM infections in 2024.
Look for more commentary on this subject.